Lp(a) levels and atherosclerotic vascular disease in a sample of patients with familial hypercholesterolemia sharing the same gene defect

被引:39
|
作者
Carmena, R
LussierCacan, S
Roy, M
Minnich, A
Lingenhel, A
Kronenberg, F
Davignon, J
机构
[1] CLIN RES INST MONTREAL, HYPERLIPIDEMIA & ATHEROSCLEROSIS RES GRP, MONTREAL, PQ H2W 1R7, CANADA
[2] UNIV VALENCIA, HOSP CLIN, ENDOCRINE SERV, E-46100 VALENCIA, SPAIN
[3] UNIV INNSBRUCK, INST MED BIOL & GENET, A-6020 INNSBRUCK, AUSTRIA
关键词
familial hypercholesterolemia; lipoprotein(a); atherosclerotic complications;
D O I
10.1161/01.ATV.16.1.129
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
There is considerable variation in the severity of cardiovascular disease among patients with familiar hypercholesterolemia (FH). Some reports have suggested that plasma lipoprotein(a) [Lp(a)] levels may explain such variation and that FH subjects deficient in LDL receptors, especially those with coronary heart disease, tend to have elevated Lp(a) levels. We have investigated the possible role of the LDL receptor in determining plasma Lp(a) levels in a genetically homogeneous FH population and the contribution of Lp(a) to cardiovascular risk. A total of 98 FH subjects and 66 healthy first- and second-degree relatives from 30 families with FH due to the French-Canadian >10-kilobase deletion of the LDL receptor gene were studied. A reference group of 392 normolipidemic French-Canadian participants in a Heart Health Survey was used for comparison. FH subjects were subdivided into subsets of 63 individuals free from atherosclerotic vascular disease (AVD) and 35 individuals with AVD. A complete cardiovascular evaluation was performed, and plasma lipid, lipoprotein, and Lp(a) levels were measured in all subjects in the absence of medication. Apolipoprotein (a) [apo(a)] phenotype was deter-mined in 112 of FH and non-FH subjects. The log-transformed values for plasma Lp(a) were not significantly different among the three groups: 0.98 +/- 0.54 (mean +/- SD) in FH subjects with AVD, 0.89 +/- 0.51 in FH subjects without AVD, and 0.82 +/- 0.64 in their relatives. The distribution of the apo(a) phenotypes did not differ between the FH and non-FH groups. Comparison of two age- and sex-matched subgroups of FH subjects, with and without AVD, failed to show any differences in Lp(a) level. However, mean Lp(a) log values in the reference group (n=392) were significantly lower than values obtained for the total FH group (0.79 +/- 0.57 versus 0.92 +/- 0.52, respectively; P<.05) but were not different from those of the unaffected family members. Thus, in our sample, the LDL receptor appears not to influence plasma Lp(a) levels; rather, these levels reflect shared apo(a) genes. The cardiovascular risk in this group of subjects with FH was related to age, male sex, total and LDL cholesterol, and higher apoB but not Lp(a) levels.
引用
收藏
页码:129 / 136
页数:8
相关论文
共 32 条
  • [11] Association between lipoprotein(a) concentrations and atherosclerotic cardiovascular disease risk in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH
    Anagnostis, Panagiotis
    Rizos, Christos, V
    Skoumas, Ioannis
    Rallidis, Loukianos
    Tziomalos, Konstantinos
    Skalidis, Emmanuel
    Kotsis, Vasileios
    Doumas, Michalis
    Kolovou, Genovefa
    Sfikas, George
    Garoufi, Anastasia
    Lambadiari, Vaia
    Dima, Ioanna
    Kiouri, Estela
    Agapakis, Dimitrios
    Zacharis, Evangelos
    Antza, Christina
    Kolovou, Vana
    Koumaras, Charalambos
    Bantouvakis, George
    Liamis, George
    Liberopoulos, Evangelos N.
    ENDOCRINE, 2022, 76 (02) : 324 - 330
  • [12] Lipoprotein(a) levels in coronary heart disease-susceptible and -resistant patients with familial hypercholesterolemia
    Nenseter, Marit S.
    Lindvig, Henriette Walaas
    Ueland, Thor
    Langslet, Gisle
    Ose, Leiv
    Holven, Kirsten B.
    Retterstol, Kjetil
    ATHEROSCLEROSIS, 2011, 216 (02) : 426 - 432
  • [13] Gene expression profiling in elderly patients with familial hypercholesterolemia with and without coronary heart disease
    Melnes, Torunn
    Bogsrud, Martin P.
    Christensen, Jacob J.
    Rundblad, Amanda
    Narverud, Ingunn
    Retterst, Kjetil
    Aukrust, Pal
    Halvorsen, Bente
    Ulven, Stine M.
    Holven, Kirsten B.
    ATHEROSCLEROSIS, 2024, 392
  • [14] Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile
    Lupo, Maria Giovanna
    Arcidiacono, Diletta
    Zaramella, Alice
    Fimiani, Fabio
    Calabro, Paolo
    Cefalu, Angelo Baldassare
    Averna, Maurizio
    D'Erasmo, Laura
    Arca, Marcello
    De Martin, Sara
    Zambon, Alberto
    Ferri, Nicola
    ATHEROSCLEROSIS PLUS, 2021, 43 : 7 - 9
  • [15] Serum lipoprotein(a) levels in patients with atherosclerotic peripheral vascular disease in Hospital Kuala Lumpur
    Hakim, N. A.
    Hafizan, M. T.
    Baizurah, M. H.
    Zainal, A. A.
    ASIAN JOURNAL OF SURGERY, 2008, 31 (01) : 11 - 15
  • [16] APOLIPOPROTEIN-B AND APOLIPOPROTEIN-E GENE POLYMORPHISMS AND ASSOCIATION WITH PLASMA-LIPIDS AND ATHEROSCLEROTIC-DISEASE IN FAMILIAL HYPERCHOLESTEROLEMIA
    HANSEN, PS
    JENSEN, HK
    MEINERTZ, H
    HANSEN, ABB
    KLAUSEN, IC
    GERDES, LU
    HORDER, M
    GREGERSEN, N
    FAERGEMAN, O
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 1994, 4 (04) : 204 - 208
  • [17] Longitudinal treatment patterns among US patients with atherosclerotic cardiovascular disease or familial hypercholesterolemia initiating lipid-lowering pharmacotherapy
    Burke, James P.
    Simpson, Ross J., Jr.
    Paoli, Carly J.
    McPheeters, Jeffrey T.
    Gandra, Shravanthi R.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2016, 10 (06) : 1470 - 1480
  • [18] Phenotypic variation in heterozygous familial hypercholesterolemia - A comparison of Chinese patients with the same or similar mutations in the LDL receptor gene in China or Canada
    Pimstone, SN
    Sun, XM
    du Souich, C
    Frohlich, JJ
    Hayden, MR
    Soutar, AK
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1998, 18 (02) : 309 - 315
  • [19] PON2 gene variants are associated with clinical manifestations of cardiovascular disease in familial hypercholesterolemia patients
    Leus, FR
    Zwart, M
    Kastelein, JJP
    Voorbij, HAM
    ATHEROSCLEROSIS, 2001, 154 (03) : 641 - 649
  • [20] TaqIB polymorphism in CETP gene: the influence on incidence of cardiovascular disease in statin-treated patients with familial hypercholesterolemia
    Mohrschladt, MF
    Beer, FVDSD
    Hofman, MK
    van der Krabben, M
    Westendorp, RGJ
    Smelt, AHM
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2005, 13 (07) : 877 - 882